Two Labs Confirm RHB-204 Kills MAP in In Vitro Studies
Two microbiology centers confirmed RHB-204’s MAP-killing capability in in vitro studies, according to the headline and available body text.
Related stories
Oracle Announces $10 Million Stock and $10 Billion Bond Deals
Oracle shares fell after the company announced stock and bond deals.
M impact | EQUITY | Nov 02, 2026, 01:47 PM UTC
Navios Maritime Holdings Raises Tender Offer Price to $16, Extends Deadline
Navios Maritime Holdings increased the tender offer price and extended the expiration date for its cash offer to purchase Series G and Series H American Depositary Shares.
M impact | EQUITY | Nov 02, 2026, 01:44 PM UTC
Krystal Biotech Q3 Net Income Falls, Revenue Rises
M impact | EQUITY | Nov 02, 2026, 01:44 PM UTC
Infineon shares rise 3.6%
M impact | EQUITY | Nov 02, 2026, 01:43 PM UTC
Out West Restaurant Group Files for Chapter 11 Bankruptcy
The filing covers 61 Outback Steakhouse locations.
M impact | EQUITY | Nov 02, 2026, 01:42 PM UTC
Birchtech Files Brief Supporting $78 Million Patent Judgment
Birchtech filed a brief in the Federal Circuit supporting the $78 million patent infringement judgment against Cert defendants.
L impact | EQUITY | Nov 02, 2026, 01:41 PM UTC